Skip to content

Study · Animal study (in vivo) · mouse · 2007

8 results

[The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].

Ma YL, Zheng Z, Li BD, Xie SJ, Li GX, Yan QH, Cai JH

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology1 Nov 2007

PMID17988589 (opens in a new tab)PepBankPUB-17988589
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In humanized nude mice bearing colon cancer, adding thymosin alpha1 to dendritic cell treatment increased tumor growth inhibition compared with dendritic cells alone.

    In plain wordsIn mice with colon cancer, adding thymosin alpha‑1 to dendritic cell treatment slowed tumor growth more than dendritic cells alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTumor growth inhibitory rate at day 58
    Study

    mousen: not reported in source

    Humanized nude mice bearing colon cancer
    Comparator
    LyDCs alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Tumor growth inhibitory rate
    60.41%
    LyDCs plus Talpha1, day 58
    Tumor growth inhibitory rate
    37.2%
    LyDCs alone, day 58

    Source sentences

    Summary
    On the 58 th day after the inoculation of tumor cells, the inhibitory rate of tumor growth was significantly higher in the group treated with LyDCs plus Talpha1 than that in the group treated with LyDCs alone (60.41% and 37.20%, respectively; P<0.01).
    1 context sentence
    Summary · context
    The in vivo antitumor activity was evaluated in the humanized nude mice after the treatment with LyDCs plus Talpha1 or LyDCs alone.
  2. 02LabIn vitro (cells)Mechanism

    In human dendritic cells, thymosin alpha1 up-regulated HLA-DR expression in immature and tumor lysate-pulsed cells.

    In plain wordsIn cells, thymosin alpha‑1 increased the immune marker HLA-DR on human dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHLA-DR expression on dendritic cells
    Study

    humann: not reported in source

    Human PBMC-derived dendritic cells (imDCs and LyDCs)
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression levels of HLA-DR, CD80, CD86 and CD83 in imDCs and LyDCs were markedly up-regulated after the stimulation with Talpha1 respectively (P<0.01).
    1 context sentence
    Summary · context
    The LyDCs were prepared from the imDCs loaded with lysate of HT-29 tumor cell line.
  3. 03LabIn vitro (cells)Mechanism

    In human dendritic cells, thymosin alpha1 up-regulated CD80 expression in immature and tumor lysate-pulsed cells.

    In plain wordsIn cells, thymosin alpha‑1 increased the immune marker CD80 on human dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD80 expression on dendritic cells
    Study

    humann: not reported in source

    Human PBMC-derived dendritic cells (imDCs and LyDCs)
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression levels of HLA-DR, CD80, CD86 and CD83 in imDCs and LyDCs were markedly up-regulated after the stimulation with Talpha1 respectively (P<0.01).
    1 context sentence
    Summary · context
    The LyDCs were prepared from the imDCs loaded with lysate of HT-29 tumor cell line.
  4. 04LabIn vitro (cells)Mechanism

    In human dendritic cells, thymosin alpha1 up-regulated CD86 expression in immature and tumor lysate-pulsed cells.

    In plain wordsIn cells, thymosin alpha‑1 increased the immune marker CD86 on human dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD86 expression on dendritic cells
    Study

    humann: not reported in source

    Human PBMC-derived dendritic cells (imDCs and LyDCs)
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression levels of HLA-DR, CD80, CD86 and CD83 in imDCs and LyDCs were markedly up-regulated after the stimulation with Talpha1 respectively (P<0.01).
    1 context sentence
    Summary · context
    The LyDCs were prepared from the imDCs loaded with lysate of HT-29 tumor cell line.
  5. 05LabIn vitro (cells)Mechanism

    In human dendritic cells, thymosin alpha1 up-regulated CD83 expression in immature and tumor lysate-pulsed cells.

    In plain wordsIn cells, thymosin alpha‑1 increased the immune marker CD83 on human dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD83 expression on dendritic cells
    Study

    humann: not reported in source

    Human PBMC-derived dendritic cells (imDCs and LyDCs)
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression levels of HLA-DR, CD80, CD86 and CD83 in imDCs and LyDCs were markedly up-regulated after the stimulation with Talpha1 respectively (P<0.01).
    1 context sentence
    Summary · context
    The LyDCs were prepared from the imDCs loaded with lysate of HT-29 tumor cell line.
  6. 06LabIn vitro (cells)Mechanism

    In co-cultures of human tumor lysate-pulsed dendritic cells and T cells, thymosin alpha1 increased IL-12 levels.

    In plain wordsIn cells, thymosin alpha‑1 increased IL-12 release in human dendritic cell and T cell cultures.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-12 secretion by LyDCs
    Study

    humann: not reported in source

    Human tumor lysate-pulsed dendritic cells co-cultured with autologous T cells
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The levels of IL-12 and IFN-gamma were also significantly increased in the presence of Talpha1
    1 context sentence
    Summary · context
    Autologous T cells were cocultured with LyDCs in the presence or absence of Talpha1 2 days later.
  7. 07LabIn vitro (cells)Mechanism

    In co-cultures of human tumor lysate-pulsed dendritic cells and T cells, thymosin alpha1 increased IFN-gamma levels.

    In plain wordsIn cells, thymosin alpha‑1 increased IFN-gamma release in human dendritic cell and T cell cultures.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIFN-gamma secretion by activated T cells
    Study

    humann: not reported in source

    Human tumor lysate-pulsed dendritic cells co-cultured with autologous T cells
    Comparator
    Without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The levels of IL-12 and IFN-gamma were also significantly increased in the presence of Talpha1 (P<0.05 and P<0.01, respectively).
    1 context sentence
    Summary · context
    Autologous T cells were cocultured with LyDCs in the presence or absence of Talpha1 2 days later.
  8. 08LabIn vitro (cells)Efficacy outcome

    In vitro, cytotoxicity of T lymphocytes induced by tumor lysate-pulsed dendritic cells treated with thymosin alpha1 was enhanced compared with untreated lysate-pulsed dendritic cells.

    In plain wordsIn lab tests, T cells primed by dendritic cells treated with thymosin alpha‑1 killed more tumor cells than T cells primed by untreated dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCytotoxicity of LyDC-induced CTLs
    Study

    humann: not reported in source

    Cytotoxic T lymphocytes induced by human tumor lysate-pulsed dendritic cells
    Comparator
    LyDCs without Talpha1
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cytotoxicity induced by LyDCs treated with Talpha1 was significantly enhanced (P<0.01) as compared with LyDCs in vitro.
    1 context sentence
    Summary · context
    The in vitro cytotoxicity of antigen specific cytotoxic T lymphocytes (CTLs) induced by LyDCs which were treated with Talpha1 was evaluated by MTT assay.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.